Stay updated with breaking news from Replimune Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Replimune Group, Inc. announced the appointment of Veleka R. Peeples-Dyer to the Company's Board of Directors effective June 1, 2023. Ms. Peeples-Dyer has served as a strategic enterprise leader at... | June 6, 2023
Responding patient images from the 75 patient snapshot in anti-PD1 failed melanoma Injected lesions ... | June 3, 2023
01.06.2023 - WOBURN, Mass., June 01, 2023 (GLOBE NEWSWIRE) - Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members ...
Replimune Group, Inc. (NASDAQ:REPL – Get Rating) – Wedbush cut their FY2024 earnings per share estimates for shares of Replimune Group in a research note issued to investors on Monday, May 22nd. Wedbush analyst R. Driscoll now expects that the company will post earnings of ($3.95) per share for the year, down from their previous […]
Replimune Group, Inc. (NASDAQ:REPL – Get Rating) has received an average rating of “Buy” from the six research firms that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued ratings on the stock in the […]